CN102947326B - 用于治疗用途的ccn3肽以及其类似物 - Google Patents

用于治疗用途的ccn3肽以及其类似物 Download PDF

Info

Publication number
CN102947326B
CN102947326B CN201180026057.3A CN201180026057A CN102947326B CN 102947326 B CN102947326 B CN 102947326B CN 201180026057 A CN201180026057 A CN 201180026057A CN 102947326 B CN102947326 B CN 102947326B
Authority
CN
China
Prior art keywords
ccn3
ccn2
peptide
fibrosis
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180026057.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102947326A (zh
Inventor
布鲁斯·里泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosalind Franklin University of Medicine and Science
Original Assignee
Rosalind Franklin University of Medicine and Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosalind Franklin University of Medicine and Science filed Critical Rosalind Franklin University of Medicine and Science
Publication of CN102947326A publication Critical patent/CN102947326A/zh
Application granted granted Critical
Publication of CN102947326B publication Critical patent/CN102947326B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
CN201180026057.3A 2010-04-02 2011-04-04 用于治疗用途的ccn3肽以及其类似物 Expired - Fee Related CN102947326B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34169410P 2010-04-02 2010-04-02
US61/341,694 2010-04-02
PCT/US2011/031121 WO2011123858A2 (en) 2010-04-02 2011-04-04 Ccn3 peptides and analogs thereof for therapeutic use

Publications (2)

Publication Number Publication Date
CN102947326A CN102947326A (zh) 2013-02-27
CN102947326B true CN102947326B (zh) 2016-02-10

Family

ID=44712870

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180026057.3A Expired - Fee Related CN102947326B (zh) 2010-04-02 2011-04-04 用于治疗用途的ccn3肽以及其类似物

Country Status (7)

Country Link
US (1) US8518395B2 (enExample)
EP (1) EP2552462B1 (enExample)
JP (1) JP5939584B2 (enExample)
CN (1) CN102947326B (enExample)
DK (1) DK2552462T3 (enExample)
ES (1) ES2561437T3 (enExample)
WO (1) WO2011123858A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
CN104749371B (zh) * 2013-12-30 2016-09-28 神州细胞工程有限公司 人肾母细胞瘤过度表达基因编码蛋白酶联免疫试剂盒
KR101576904B1 (ko) * 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
EP3711772A1 (en) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN115433776B (zh) * 2022-09-30 2023-12-22 中国医学科学院阜外医院 Ccn3在调控血管平滑肌细胞钙化中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036962A2 (en) * 2004-09-28 2006-04-06 Lau Lester F Compositions and methods for modulating tissue regeneration and chemotactic responses
US20060178332A1 (en) * 2005-01-10 2006-08-10 Riser Bruce L Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
WO2008035024A1 (en) * 2006-09-22 2008-03-27 The Queen's University Of Belfast Ccn3 peptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112088B1 (en) 1998-09-08 2010-10-27 Henry Ford Health System Method for detecting connective tissue growth factor for diagnosing a renal disorder
US20030059768A1 (en) 2000-02-25 2003-03-27 Corine Vernet Novel polypeptides and nucleic acids encoding same
US20040009940A1 (en) 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
FR2825928B1 (fr) 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
EP1382347A1 (en) 2002-07-17 2004-01-21 UNIVERSITE PARIS 7 - Denis DIDEROT Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
EP1608970A4 (en) 2003-03-31 2006-06-14 Munin Corp CCN3 COMPOSITIONS AND METHODS
FR2858234B1 (fr) * 2003-08-01 2007-09-14 Centre Nat Rech Scient Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
JP4834677B2 (ja) * 2005-01-10 2011-12-14 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス Ｃｃｎ３によるｃｃｎ２の調節ならびに線維症、硬化症および他の疾患におけるその治療的可能性ならびに診断的可能性

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036962A2 (en) * 2004-09-28 2006-04-06 Lau Lester F Compositions and methods for modulating tissue regeneration and chemotactic responses
US20060178332A1 (en) * 2005-01-10 2006-08-10 Riser Bruce L Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
WO2008035024A1 (en) * 2006-09-22 2008-03-27 The Queen's University Of Belfast Ccn3 peptide
US20100004169A1 (en) * 2006-09-22 2010-01-07 The Queen's University Of Belfast CCN3 peptide

Also Published As

Publication number Publication date
EP2552462A2 (en) 2013-02-06
CN102947326A (zh) 2013-02-27
WO2011123858A2 (en) 2011-10-06
WO2011123858A3 (en) 2011-11-24
US8518395B2 (en) 2013-08-27
JP5939584B2 (ja) 2016-06-22
EP2552462A4 (en) 2013-12-18
EP2552462B1 (en) 2015-12-16
ES2561437T3 (es) 2016-02-26
US20110250180A1 (en) 2011-10-13
JP2013523778A (ja) 2013-06-17
DK2552462T3 (en) 2016-02-08

Similar Documents

Publication Publication Date Title
CN102947326B (zh) 用于治疗用途的ccn3肽以及其类似物
US12024544B2 (en) CCN3 and CCN3 peptides and analogs thereof for therapeutic use
Brigstock The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family
Daniel et al. Thrombospondin-1 is a major activator of TGF-β in fibrotic renal disease in the rat in vivo
Fan et al. Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro
Chien et al. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis
KR20210134699A (ko) 뉴레귤린-4 화합물 및 사용 방법
JP2010096748A (ja) アトピー性皮膚炎の検出方法および予防・治療剤のスクリーニング方法
US7780949B2 (en) Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
EP1841316B1 (en) CCN3 protein for use in the treatment and diagnosis of renal diseases
HUT70297A (en) Human bone derived insulin like growth factor binding protein
CN108431033A (zh) 骨生长病症的治疗
US20070059314A1 (en) Novel anti-angiogenic agent and its use in particular within the framework of the treatment of cancer
Perbal et al. The CCN family of proteins: an overview
JP3922345B2 (ja) 生理活性ペプチド
US20030073117A1 (en) Novel protein and gene encoding the protein
CN110133274A (zh) Igfbpl1作为标志物在制备心血管疾病诊断试剂中的应用
Lin Weng et al. Nogo-C regulates post myocardial infarction fibrosis through the interaction with ER Ca 2 leakage channel Sec61α in mouse hearts
Aguzzi et al. Intracellular targets of RGDS peptide in melanoma cells
Laeremans et al. Development of tools for visualization of Frizzled-1 and-2
Lin The nuclear actions of IGFBP-3
HK1072005A1 (zh) 平滑肌细胞增殖的调节
HK1072005B (en) Modulation of smooth muscle cell proliferation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160210

CF01 Termination of patent right due to non-payment of annual fee